ProCE Banner Activity

Optimizing the Use of BTK Inhibitors in B-Cell Malignancies: Insights for the Multidisciplinary Team

Slideset Download
These downloadable slides from our live meeting series on BTK inhibitors review the current clinical rationale and most recent data on the use of ibrutinib and acalabrutinib for patients with MCL, CLL, or WM.

Released: September 10, 2018

Expiration: September 09, 2019

No longer available for credit.

Share

Faculty

Christopher R. Flowers

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Andrew D. Zelenetz

Andrew D. Zelenetz, MD, PhD

Associate Professor, Department of Medicine
Cornell University Medical College
Chief, Lymphoma Service
Memorial Sloan-Kettering Cancer Center
New York, New York

Provided by

Provided by Purdue University College of Pharmacy
ProCE Banner

Supporters

This activity is supported by an educational grant from

AstraZeneca

Program Director Disclosure

Program Director

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Andrew D. Zelenetz, MD, PhD

Associate Professor, Department of Medicine
Cornell University Medical College
Chief, Lymphoma Service
Memorial Sloan-Kettering Cancer Center
New York, New York